Response Genetics Renews Agreement With Taiho Pharmaceutical Co., Ltd. to Provide Molecular Analyses for Cancer LOS ANGELES, July 17, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has extended its agreement with Taiho Pharmaceutical Co., Ltd. to provide testing and analyses services for specified molecular markers used in research, diagnosis and the therapeutic treatment of cancer. Under the terms of the agreement, Response Genetics will receive a minimum of $950,000 for services provided during the extended term of January 1 through December 31, 2013. "Response Genetics has and continues to provide Taiho with a comprehensive portfolio of gene expression assays and we are pleased to extend this relationship," said Thomas Bologna, Chairman and CEO of Response Genetics. "Response Genetics and Taiho share a commitment to provide services that foster the development of patient-centered medical treatment and we believe that the testing services resulting from this collaboration will yield actionable results important to patient care." About Response Genetics, Inc. Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens.The Company's principal customers include oncologists and pathologists.In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.The Company's headquarters is located in Los Angeles, California.For more information, please visit www.responsegenetics.com. About Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing innovative medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life.The company was established in 1963 and its headquarters is located in Tokyo, Japan. Forward-Looking Statement Notice Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties.Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission.Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements.These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. CONTACT: Investor Relations Contact: Peter Rahmer Trout Group 646-378-2973 Company Contact: Thomas A. Bologna Chairman & Chief Executive Officer 323-224-3900 Response Genetics Logo
Response Genetics Renews Agreement With Taiho Pharmaceutical Co., Ltd. to Provide Molecular Analyses for Cancer
Press spacebar to pause and continue. Press esc to stop.